TY - JOUR

T1 - ДИНАМИКА ПСИХОЭМОЦИОНАЛЬНОГО СОСТОЯНИЯ ПАЦИЕНТОВ С ХРОНИЧЕСКИМ ГЕПАТИТОМ С (F1-F3) НА ФОНЕ ТЕРАПИИ ПРЕПАРАТОМ БИЦИКЛОЛ

AU - Козлов, К.В.

AU - Мухтаров, Р.М.

AU - Жданов, Константин Валерьевич

AU - Сукачев , В.С.

AU - Саулевич, А.В.

AU - Ляшенко, Ю.И.

AU - Буланьков, Ю.И.

PY - 2025/3/15

Y1 - 2025/3/15

N2 - Purpose of the study. To evaluate the psycho-emotional state in patients with chronic viral hepatitis C before and after treatment with bicyclol. Materials and methods. The study included 124 male patients with chronic hepatitis C aged 20 to 52 years (average 34.7 ± 6.5). The patients were randomized into 2 groups: group I, including 83 patients with mild to moderate liver fibrosis (F1-2 according to METAVIR); and group II – 41 patients with severe liver fibrosis (F3 according to METAVIR). After antiviral therapy with direct antiviral agents, patients in each group were divided into 2 subgroups: an experimental group, which was prescribed the bicyclol to potentiate the anti-inflammatory effect, and a control group – without pathogenetic therapy. The psycho-emotional state was evaluated using the “Well-being, activity, mood” methodology. Results. As a result of complex etiopathogenetic therapy, a decrease in liver stiffness was observed in both patients with moderate and severe liver fibrosis. In patients of the experimental subgroup with moderate liver fibrosis, a decrease in liver density was observed from 7.10 kPa [6.70; 8.70] to 5.80 kPa [5.60; 7.00] (p = 0.008), and in the control subgroup – up to 6.40 kPa [5.80; 7.40] (p = 0.03), while in the experimental subgroup the decrease in liver density was significantly more pronounced (p = 0.04). When taking the questionnaire “Well-being, activity, mood” by patients with mild and moderate liver fibrosis before starting antiviral therapy, the final scores were in the normal range: total score 5.77 [5.53; 6.03], “well-being” indicator 5.80 [5.60; 6.20], “activity” indicator 5.30 [5.00; 5.60], “mood” indicator 6.10 [6.00; 6.20]. At the same time, patients with severe fibrosis had statistically significantly lower results for the studied indicators (p

AB - Purpose of the study. To evaluate the psycho-emotional state in patients with chronic viral hepatitis C before and after treatment with bicyclol. Materials and methods. The study included 124 male patients with chronic hepatitis C aged 20 to 52 years (average 34.7 ± 6.5). The patients were randomized into 2 groups: group I, including 83 patients with mild to moderate liver fibrosis (F1-2 according to METAVIR); and group II – 41 patients with severe liver fibrosis (F3 according to METAVIR). After antiviral therapy with direct antiviral agents, patients in each group were divided into 2 subgroups: an experimental group, which was prescribed the bicyclol to potentiate the anti-inflammatory effect, and a control group – without pathogenetic therapy. The psycho-emotional state was evaluated using the “Well-being, activity, mood” methodology. Results. As a result of complex etiopathogenetic therapy, a decrease in liver stiffness was observed in both patients with moderate and severe liver fibrosis. In patients of the experimental subgroup with moderate liver fibrosis, a decrease in liver density was observed from 7.10 kPa [6.70; 8.70] to 5.80 kPa [5.60; 7.00] (p = 0.008), and in the control subgroup – up to 6.40 kPa [5.80; 7.40] (p = 0.03), while in the experimental subgroup the decrease in liver density was significantly more pronounced (p = 0.04). When taking the questionnaire “Well-being, activity, mood” by patients with mild and moderate liver fibrosis before starting antiviral therapy, the final scores were in the normal range: total score 5.77 [5.53; 6.03], “well-being” indicator 5.80 [5.60; 6.20], “activity” indicator 5.30 [5.00; 5.60], “mood” indicator 6.10 [6.00; 6.20]. At the same time, patients with severe fibrosis had statistically significantly lower results for the studied indicators (p

KW - bicyclol

KW - liver fibrosis

KW - psycho-emotional state

KW - сhronic hepatitis C

UR - https://www.mendeley.com/catalogue/31623991-9b15-37af-b7ba-b8fad5b644ff/

U2 - 10.22625/2072-6732-2025-17-1-81-89

DO - 10.22625/2072-6732-2025-17-1-81-89

M3 - статья

VL - 17

SP - 81

EP - 89

JO - Журнал инфектологии

JF - Журнал инфектологии

SN - 2072-6732

IS - 1

ER -